Medical Therapy for Obesity

Gastrointestinal Endoscopy Clinics of North America

Volumn 21, Issue 2, 2011, Pages 203-212

  Abu Dayyeh, Barham K ^a,b   Kaplan, Lee M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diet; Lifestyle modification; Medications; Obesity; Pharmacotherapy

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIOBESITY AGENT; BILE ACID; BUPROPION PLUS ZONISAMIDE; CARBOHYDRATE; CETILISTAT; DOPAMINE; EXENDIN 4; FENFLURAMINE; FLUOXETINE; GLUCOSE; INSULIN; LIPID; LIRAGLUTIDE; LORCASERIN; METRELEPTIN; NORADRENALIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENTERMINE RESIN; PLACEBO; PRAMLINTIDE; RETINOL; SERTRALINE; SIBUTRAMINE; SUGAR; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP;

APPETITE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; DEFECATION HABIT; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENERGY EXPENDITURE; ENTEROENDOCRINE CELL; FECES INCONTINENCE; FLATULENCE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER INJURY; LONG TERM CARE; LOW DRUG DOSE; MALABSORPTION; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SATIETY; SIDE EFFECT; SMALL INTESTINE; STEATORRHEA; STOMACH MUCOSA; TACHYCARDIA; TREATMENT DURATION; VITAMIN DEFICIENCY; WEIGHT REDUCTION;

HUMANS; LIPASE; NEUROTRANSMITTER AGENTS; OBESITY;

EID: 79955741633     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2011.02.006     Document Type: Review

References (43)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
2. Guh D.P., Zhang W., Bansback N., et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
3. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295(13):1549-1555.
4. Nguyen N.T., Magno C.P., Lane K.T., et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008, 207(6):928-934.
5. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981, 282(6279):1847-1851.
6. Wing R.R. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial. Arch Intern Med 2010, 170(17):1566-1575.
7. Sjostrom L., Narbro K., Sjostrom C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357(8):741-752.
8. Ogden C.L., Yanovski S.Z., Carroll M.D., et al. The epidemiology of obesity. Gastroenterology 2007, 132(6):2087-2102.
9. Witkamp R.F. Current and future drug targets in weight management. Pharm Res 2010, [Epub ahead of print].
10. Clinical Guidelines on the Identification Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S-209S.
11. Kaplan L.M. Pharmacologic therapies for obesity. Gastroenterol Clin North Am 2010, 39(1):69-79.
12. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, 4. CD004094.
13. Bray G.A., Greenway F.L. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007, 59(2):151-184.
14. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369(9555):71-77.
15. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142(7):532-546.
16. Hutton B., Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004, 80(6):1461-1468.
17. Franz M.J., VanWormer J.J., Crain A.L., et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007, 107(10):1755-1767.
18. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004, 3. CD004094.
19. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27(12):1437-1446.
20. Kopelman P., Groot Gde H., Rissanen A., et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010, 18(1):108-115.
21. Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007, 117(1):13-23.
22. Theodorakis M.J., Carlson O., Michopoulos S., et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006, 290(3):E550-E559.
23. Jang H.J., Kokrashvili Z., Theodorakis M.J., et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007, 104(38):15069-15074.
24. Hansotia T., Maida A., Flock G., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007, 117(1):143-152.
25. Astrup A., Rossner S., Van Gaal L., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374(9701):1606-1616.
26. Cummings B.P., Stanhope K.L., Graham J.L., et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010, 59(10):2653-2661.
27. Singh-Franco D., Robles G., Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2007, 29(4):535-562.
28. Roth J.D., Roland B.L., Cole R.L., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008, 105(20):7257-7262.
29. Halford J.C., Boyland E.J., Blundell J.E., et al. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010, 6(5):255-269.
30. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337(9):581-588.
31. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353(20):2111-2120.
32. James W.P., Caterson I.D., Coutinho W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363(10):905-917.
33. Astrup A., Madsbad S., Breum L., et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9653):1906-1913.
34. Goldstein D.J., Rampey A.H., Enas G.G., et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994, 18(3):129-135.
35. Anchors M. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity. Arch Intern Med 1997, 157(11):1270.
36. Smith S.R., Prosser W.A., Donahue D.J., et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009, 17(3):494-503.
37. Smith S.R., Weissman N.J., Anderson C.M., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010, 363(3):245-256.
38. Ioannides-Demos L.L., Piccenna L., McNeil J.J. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011, 2011:179674.
39. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005, 8(5):571-578.
40. Nicholson J.R., Peter J.C., Lecourt A.C., et al. Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function. J Neuroendocrinol 2007, 19(12):974-982.
41. Greenway F.L., Fujioka K., Plodkowski R.A., et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376(9741):595-605.
42. Wadden T.A., Foreyt J.P., Foster G.D., et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011, 19(1):110-120.
43. Froguel P., Blakemore A.I. The power of the extreme in elucidating obesity. N Engl J Med 2008, 359(9):891-893.